BriSTAR has developed a flexible cell therapy platform sparing from preclinical process development to clinical material manufacturing that supports the development of a new generation of personalized cell therapy products (STAR-T and enTCR-T products).
The company’s enhanced platform expedites timelines and support clinical development of our pipeline products.

  • Phase I clinical site
  • CMC facilities
  • CMC site
  • R&D site